James Diggans

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The promise of personalized medicine will require rigorously validated molecular diagnostics developed on minimally invasive, clinically relevant samples. Measurement of DNA mutations is increasingly common in clinical settings but only higher-prevalence mutations are cost-effective. Patients with rare variants are at best ignored or, at worst,(More)
  • 1